Mercer Global Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Mercer Global Advisors's GLUE Position: Q3 2026 in Review
Mercer Global Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 10,631 shares — an estimated $257K sold.
Mercer Global Advisors first reported a position in GLUE in Q4 2025 and held it in 3 quarters. The position peaked at $257K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Mercer Global Advisors reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
- Mercer Global Advisors sold 10,631 Monte Rosa Therapeutics shares in Q3 2026, an estimated $257K.
- Mercer Global Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and held it in 3 quarters.
- Mercer Global Advisors's Monte Rosa Therapeutics position peaked at $257K in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.